Form 4: Pfizer Executive Vice President Sally Susman Acquires Stock Appreciation Rights

Executive Vice President of Pfizer, Sally Susman, reports acquisition of stock appreciation rights convertible to Pfizer common stock.

Summary

• Sally Susman, an Executive Vice President at Pfizer Inc., filed a Form 4 on March 6, 2025, reporting a transaction.
• On March 4, 2025, Susman acquired 156,992 stock appreciation rights (SARs) at an exercise price of $25.75.
• These SARs are subject to vesting requirements and will be settled in shares of Pfizer common stock on March 4, 2030, the fifth anniversary of the grant date.
• Following the reported transaction, Susman directly owns 156,992 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects routine executive compensation.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting and settlement of the stock appreciation rights in 2030 suggests a long-term incentive for the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates compensation and alignment of executive interests with shareholder value.

Stakeholder Impact

• The acquisition of stock appreciation rights aligns the executive's interests with those of shareholders, incentivizing long-term value creation.

Key Dates